Literature DB >> 14871409

Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells.

Sinee Disthabanchong1, Hatim Hassan, Charles L McConkey, Kevin J Martin, Esther A Gonzalez.   

Abstract

BACKGROUND: Homologous down-regulation/desensitization of the parathyroid hormone receptor (PTH1R)/adenylate cyclase system has been demonstrated in uremia, and may contribute to parathyroid hormone (PTH) resistance; however, additional studies have shown that parathyroidectomy fails to normalize the down-regulation of the PTH1R. The present studies were designed to test directly, in vitro, the hypothesis that factors circulating in the uremic environment, other than PTH, decrease the response of osteoblastic cells to PTH.
METHODS: Studies were conducted in confluent cultures of UMR 106-01 osteoblast-like cells. Uremic ultrafiltrate (UUF) was obtained from patients on hemodialysis. Cells were exposed to media containing 50% uremic ultrafiltrate for periods of up to 72 hours. Control cultures were exposed to a buffered salt solution containing a comparable ionic composition to that of the UUF. PTH-stimulated cyclic adenosine monophosphate (cAMP) generation was determined by radioimmunoassay (RIA), PTH binding and PTH1R mRNA levels were determined by radioligand binding and Northern analysis, respectively.
RESULTS: PTH-stimulated cAMP generation from cultures treated with uremic ultrafiltrate for 48 hours was 1385.8 +/- 183.2 pmol/culture/5 minutes, whereas control cultures generated 2389.5 +/- 271 pmol cAMP/culture/5 minutes (P < 0.05). PTH binding was decreased by 30% in cultures incubated with UUF as compared to controls. The decrease in binding induced by UUF was accompanied by a decrease in PTH1R mRNA levels.
CONCLUSION: These findings demonstrate that factors present in UUF decrease PTH-stimulated cAMP generation by a mechanism that involves a decrease in the levels of PTH1R mRNA levels. Thus, the skeletal resistance to PTH in the setting of chronic kidney disease, may be explained, at least in part, by circulating factors other than PTH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871409     DOI: 10.1111/j.1523-1755.2004.00472.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?

Authors:  Pieter Evenepoel; Bjorn Meijers
Journal:  Nat Rev Nephrol       Date:  2012-10-09       Impact factor: 28.314

Review 2.  Uremic toxin and bone metabolism.

Authors:  Yoshiko Iwasaki; Hideyuki Yamato; Tomoko Nii-Kono; Ayako Fujieda; Motoyuki Uchida; Atsuko Hosokawa; Masaru Motojima; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Ankle-brachial index and bone turnover in patients on dialysis.

Authors:  Gérard M London; Sylvain J Marchais; Alain P Guérin; Marie-Christine de Vernejoul
Journal:  J Am Soc Nephrol       Date:  2014-09-17       Impact factor: 10.121

4.  Expression of bone type 1 PTH receptor in rats with chronic renal failure.

Authors:  Michio Kuwahara; Seiji Inoshita; Yukiko Nakano; Yoshio Terada; Yoshiro Takano; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

5.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

Review 6.  Bone health and vascular calcification relationships in chronic kidney disease.

Authors:  Goce B Spasovski
Journal:  Int Urol Nephrol       Date:  2007-09-26       Impact factor: 2.370

7.  The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control.

Authors:  Mario Cozzolino; Florjan Mehmeti; Paola Ciceri; Elisa Volpi; Andrea Stucchi; Irene Brenna; Daniele Cusi
Journal:  Int J Nephrol       Date:  2011-03-29

8.  CCN1/Cyr61 Is Required in Osteoblasts for Responsiveness to the Anabolic Activity of PTH.

Authors:  Gexin Zhao; Elliot W Kim; Jie Jiang; Chimay Bhoot; Kemberly R Charles; Jongseung Baek; Subburaman Mohan; John S Adams; Sotirios Tetradis; Karen M Lyons
Journal:  J Bone Miner Res       Date:  2020-08-17       Impact factor: 6.390

Review 9.  The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD.

Authors:  Chien-Lin Lu; Dong-Feng Yeih; Yi-Chou Hou; Guey-Mei Jow; Zong-Yu Li; Wen-Chih Liu; Cai-Mei Zheng; Yuh-Feng Lin; Jia-Fwu Shyu; Remy Chen; Chung-Yu Huang; Kuo-Cheng Lu
Journal:  Nutrients       Date:  2018-12-03       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.